<DOC>
	<DOCNO>NCT00060008</DOCNO>
	<brief_summary>RATIONALE : New image procedure fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) magnetic resonance ( MR ) perfusion imaging may improve ability detect disease progression , help doctor predict patient 's response treatment , help plan effective treatment . PURPOSE : This diagnostic trial study well FDG-PET MR perfusion image work find disease progression determine response treatment patient neurofibromatosis 1 plexiform neurofibroma .</brief_summary>
	<brief_title>Fludeoxyglucose F 18 Positron Emission Tomography Magnetic Resonance Perfusion Imaging Patients With Neurofibromatosis 1 Plexiform Neurofibroma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) MR perfusion study predict plexiform neurofibroma growth rate patient neurofibromatosis 1 . - Determine whether FDG-PET MR perfusion study predict likelihood response patient undergoing investigational treatment plexiform neurofibroma . - Identify neuroimaging characteristic distinguish patient respond therapy completion treatment . OUTLINE : - Stratum 1 : Patients undergo MR perfusion scan gadopentetate dimeglumine fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) baseline quantitative MRI evaluation baseline 1 year . - Stratum 2 : Patients undergo quantitative MRI , MR perfusion scan gadopentetate dimeglumine , FDG-PET baseline 1 year . PROJECTED ACCRUAL : A total 48 patient ( 32 stratum 1 16 stratum 2 ) accrue study .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma , Plexiform</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Stratum 1 : Diagnosis neurofibromatosis 1 ( NF1 ) plexiform neurofibroma At high risk progression , define follow : Anatomic location progression carry high risk impairment function , pain , disfigurement ( e.g. , neck/mediastinum , paraspinal nerve root , orbit , face ) Tumors patient , family , caregiver believe increase size within past year , appear stable standard clinical radiographic measure No plexiform neurofibromas small , cause pain functional impairment , likely cause pain functional impairment succeed 12 month Stratum 2 : Diagnosis NF1 progressive plexiform neurofibroma Neurofibroma progression document increase lesion size MRI Currently enrol clinical therapeutic trial Children 's Hospital Philadelphia PATIENT CHARACTERISTICS : Age 25 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Stratum 1 : No prior concurrent chemotherapy No concurrent enrollment chemotherapy clinical trial Stratum 2 : At least 4 week since prior chemotherapy Endocrine therapy Not specify Radiotherapy At least 6 week since prior radiotherapy ( stratum 2 ) Surgery Prior surgery progressive plexiform neurofibroma allow incompletely resect measurable disease remain ( stratum 2 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>neurofibromatosis type 1</keyword>
	<keyword>plexiform neurofibroma</keyword>
</DOC>